Role of adiponectin and nsafatin_1 hormones in polycystic ovary syndrome: systematic review

Document Type : Review Article

Authors

1 M.Sc. in Midwifery, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

2 Ph.D student, Department of Reproductive Health, Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Instructor, Department of Midwifery, School of Nursing and

3 Ph.D student, Department of Reproductive Health, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran.

Abstract

Introduction: Adiponectin and nesfatin are the hormones which secret from adipose tissue in response to extracellular stimuli. Lipid metabolism and insulin sensitivity have role in regulating energy balance. This review study was performed with aim to investigate the effect of adiponectin and nesfatin-1 in polycystic ovary syndrome (PCOS).
 Methods: In this review article, to find the articles, search was performed in databases of pubmed, google scholar, Scopus, SID with the keywords of Adiponectin, Nesfatin, and polycystic ovary syndrome from 2003 to 2017. This study was written based on PRISMA checklist. The quality of the extracted articles was evaluated based on the STORBE, CONSORT and CASP checklist of contents, and ultimately 21 articles were assessed.
 Results: In most studies, adiponectin levels have been shown to decrease in patients with PCOS. Also, the studies have shown contradictory results about nesfatin levels and PCOS.
Conclusion: Studies have shown that adiponectin and nesfatin may play a role in PCOS and likely control and regulate this hormone in the body and can help to treat people with PCOS or prevent it and reduce the economic burden on the family and society.

Keywords


  1. Toscani KM, Mario MF, Radavelli-Bagatini S, Spritzer PM. Insulin resistance is not strictly associated with energy intake or dietary Macronutrient composition in women with polycystic ovary syndrome. Nutr Res 2011; 31(2):97-103.
  2. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006; 29(1):278-85.
  3. Tehranian N, Esmaielzade M, Pourali Roudbeneh Sh, Saber Mashhad Touroghy A. [The investigate Adiponektins (Nesfatin_1, visfatin,Apelin) in metabolic setting and fertility ]. Tehran, Da publisher; 2016.
  4. Fazeli Daryasari SR, Razavinia F, Tork Tatari F, Pahlavan F, Tehranian N. The Role of Adiponectin in Gestational Diabetes Mellitus, Preeclampsia and Obesity during pregnancy: A Systematic Review. Iranian Journal of Endocrinology and Metabolism 2018: 19(5):370-383.
  5. Pahlavan F, Tork Tatari F, Fazeli S, Razavinia F, Tehranian N.Role of Adiponectin Hormone in Fertility and Sterility: A Systematic Review. Iran J Obstet Gynecol Infertil 2018 : 21(5):97-107.
  6. Fazeli R, Razavinia F, Tehranian N. [The role of Adiponektin in the regulation of Metabolic & body system & Reproductive Health ]. Tehran, Da publisher; 2017.
  7. Razavinia F, Fazeli R, Tatari F, Pahlavan F, Tehranian N. The Role of Orexin A During Pregnancy and Lactation and Sudden Infant Death (SIDS): A Systematic Review. J Rafsanjan Univ Med Sci 2017; 16(8):769-88.
  8. Razavinia F, Fazeli R, Tehranian N. The role of Orexin in the regulation of Metabolic& body system & Reproductive HealthThe role of Orexin in metabolic setting ].Tehran, Da publisher. 2017 (Persian book).
  9. Razavinia F. Evaluation of orexin A serum levels of mother's blood and cord blood after delivery and comparison of this in vaginal delivery and elective cesarean. Master's Thesis, Tarbiat Modares University, 2017.
  10. Razavinia F, Tehranian N, Tork Tatari F, Bidhendi Yarandi R, Ramezani Tehrani F. The Postpartum Marital Satisfaction, Maternal Serum Concentration of Orexin-A and Mode of Delivery. J Sex Marital Ther 2019; 45(6):488-496.
  11. Fazeli Daryasari SR, Tehranian N, Kazemnejad A, Razavinia F, Tork Tatari F, Pahlavan F. Adiponectin levels in maternal serum and umbilical cord blood at birth by mode of delivery: Relationship to anthropometric measurements and fetal sex. BMC Pregnancy Childbirth 2019; 19(1):344.
  12. Saldanha JF, Carrero JJ, Lobo JC, Stockler-Pinto MB, Leal VO, Calixto A, et al. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation?. Regul Pept 2012; 173(1-3):82-5.
  13. Angelone T, Filice E, Pasqua T, Amodio N, Galluccio M, Montesanti G, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci 2013; 70(3):495-509.
  14. Amjadi FS, Salehi E, Haghjooy Javanmard SH. Leptin and Fertility. Journal of Isfahan Medical School 2011; 28(121):1701-13.
  15. Dos Santos E, Serazin V, Morvan C, Torre A, Wainer R, de Mazancourt P, et al. Adiponectin and leptin systems in human endometrium during window of implantation. Fertil Steril 2012; 97(3):771-8.
  16. Trujillo EM, Scherer EP. Adipose Tissue-Derived Factors: Impact on Health and Disease. Endocr Rev 2006; 27(7):762-78.
  17. Takemura Y, Osuga Y, Yamauchi T, Kobayashi M, Harada M, Hirata T, et al. Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology. 2006; 147(7):3203-10.
  18. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34(1):12-8.
  19. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004; 60(4):500-507.
  20. Comim FV, Hardy K, Franks S. Adiponectin and its receptors in the ovary: further evidence for a link between obesity and hyperandrogenism in polycystic ovary syndrome. PLoS One 2013; 8(11):e80416.
  21. Artimani T, Saidijam M, Aflatoonian R, Ashrafi M, Amiri I, Yavangi M, et al. Downregulation of adiponectin system in granulosa cells and low levels of HMW adiponectin in PCOS. J Assist Reprod Genet 2016; 33(1):101-10.
  22. Kawashima S, Sakihara S, Kageyama K, Nigawara T, Suda T. Corticotropin releasing factor (CRF) is involved in the acute anorexic effect of alpha-melanocyte stimulating hormone: A study using CRF-deficient mice. Peptides 2008; 29(12):2169-74.
  23. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88(7):3236-40.
  24. Bik W, Baranowska-Bik A, Wolinska-Witort E, Chmielowska M, Martynska L, Baranowska B. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome. Gynecol Endocrinol 2007; 23(6):325-31.
  25. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009; 6(1):27-35.
  26. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120(2):91-5.
  27. Azami M, Darvishi Z, Borji M, Sayehmiri K. Helicobacter pylori infection is associated with anemia in pregnant women- a meta-analysis study. Iran J Med Microbiol 2016; 10(1):1-7.
  28. Taghipour A, Shakeri MT, Yousefi R, Barzanouni S. Assessment of Randomized Controlled Clinical Trials articles in the Journal of Dental School, Mashhad University of Medical Sciences: Published 2003-2015. J Mash Dent Sch 2017; 41(1):11-20.
  29. Bahri N, Latifnejad Roudsari R. A Critical Appraisal of Research Evidence on Iranian Women’s Attitude towards Menopause. Iran J Obstet Gynecol Infertil 2016; 18(178):1-11.
  30. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003; 18(9):1790-6.
  31. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(8):3626-31.
  32. Orio F Jr, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88(6):2619-23.
  33. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 61(6):738-67.
  34. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol 2005; 152(3):389-94.
  35. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2005; 83(6):1708-16.
  36. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchón R, Luque-Ramírez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006; 21(9):2257-65.
  37. Gulcelik NE, Aral Y, Serter R, Demir Y, Çulha C. Adiponectin is an independent determinant of insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22(9):511-5.
  38. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 2008; 89(5):1200-8.
  39. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009; 15(3):297-307.
  40. Katsikis I, Mouslech T, Kourtis A, Panidis D, Georgopoulos NA. Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance. Fertil Steril 2009; 91(4):e3.
  41. Yilmaz M, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25(4):246-52.
  42. Olszanecka-Glinianowicz M, Kuglin D, Dąbkowska-Huć A, Skałba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 154(1):51-6.
  43. Mazloomi S, Sharifi F, Hajihosseini R, Kalantari S, Mazloomzadeh S. Association between Hypoadiponectinemia and Low Serum Concentrations of Calcium and Vitamin D in Women with Polycystic Ovary Syndrome. ISRN Endocrinol 2012; 2012:949427.
  44. Benrick A, Chanclon B, Micallef P, Wu Y, Hadi L, Shelton JM, et al. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model. Proc Natl Acad Sci U S A 2017; 114(34):E7187-E7196.
  45. Deniz R, Gurates B, Aydin S, Celik H, Sahin I, Baykus Y, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 2012; 42(3):694-9.
  46. Ademoglu EN, Gorar S, Carlıoglu A, Yazıcı H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest 2014; 37(8):715-719.
  47. Binnetoğlu E, Erbağ G, Gencer M, Turkön H, Aşik M, Güneş F, et al. Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea 2014; 30(1):201-204.
  48. Artia Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1):79-83.
  49. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty_acid oxidation by activating AMP – activated protein kinas. Nat Med 2002; 8(11): 1288_95.
  50. Yamauchi T ,Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob mice from diabetes and Apo Edeficient mice from atherosclerosis. J Biol Chem 2003; 278(4):2461-8.
  51. Ehramann DA. Polycystic ovary syndrome. N Engle J Med 2005; 352(12):1223-36.
  52. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgen decrease plasma adiponectin, an insulinsensitizing adipocyte-derived protein. Diabetes 2002; 51(9):2734-41.
  53. Gutman G, Barak V, Maslovitz S, Amit A, Lessing B, Geva E. Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril 2009; 91(5):1837-41.
  54. Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol 2008; 284(1-2):38-45.
  55. Chabrolle C, Tosca L, Crochet S, Tesseraud S, Dupont J. Expression of adiponectin and its receptors (AdipoR1 and AdipoR2) in chicken ovary: potential role in ovarian steroidogenesis. Domest Anim Endocrinol 2007; 33(4):480-7.
  56. Dunaif A. Insuline resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18(6):774-800.
  57. Hirose H, Yammato Y, Senio-Yoshihara Y, Kawabe H, Satio I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 2010; 17(12):1201-11.
  58. Yosten GL, Samson WK. The orexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am J Physiol Regul Integr Comp Physiol 2010; 298(6):1642-7.
  59. Price CJ, Samson WK, Ferguson AV. Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 2008; 1230: 99-106.
  60. Garcia-Galiano D, Tena-sempere M. Emerging roles of NUCB2/nesfatin-1 in the metabolic control of reproduction. Curr Pharm Des 2013; 19(39): 6966-72.
  61. Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mous islet b-cells. Endocr J 2011; 58(4):305-13.